Analysts Expect Opiant Pharmaceuticals, Inc. (OPNT) to Announce -$0.87 EPS
Wall Street analysts forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will post earnings of ($0.87) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Opiant Pharmaceuticals’ earnings. Opiant Pharmaceuticals posted earnings per share of ($0.52) during the same quarter last year, which indicates a negative year-over-year growth rate of 67.3%. The business is expected to report its next quarterly earnings report on Monday, October 30th.
On average, analysts expect that Opiant Pharmaceuticals will report full year earnings of $2.36 per share for the current fiscal year. For the next financial year, analysts anticipate that the firm will post earnings of ($4.83) per share. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Opiant Pharmaceuticals.
Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 6th.
Opiant Pharmaceuticals (NASDAQ OPNT) traded down 2.56% during trading on Thursday, reaching $35.84. The company had a trading volume of 12,273 shares. The firm’s 50 day moving average price is $27.21 and its 200 day moving average price is $12.29. Opiant Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $51.90. The firm has a market capitalization of $72.61 million, a PE ratio of 13.48 and a beta of -0.75.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.